Business
CB Scientific, Inc. Executes Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd.
CB Scientific, Inc. Executes Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd..
About this update from Cardiac Biotech Solutions Inc.
[{"type":"text","content":"Partnership to provide high volume manufacturing capability and facilitate obtaining requisite government approvalsESCONDIDO, CA / ACCESSWIRE / December 7, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced Shenzhen Pump Medical System Co., Ltd. (SPMS), a leading Chinese developer, manufacturer, and distributor of medical equipment and devices focusing on cardiovascular diagnostic systems, has issued a formal Letter of Intent to manufacture the Company's products targeting key Southeast Asia markets including China, Malaysia, Thailand, Indonesia, and Singapore."This critical collaboration is indispensable, not only by establishing a prominent local manufacturing relationship in the region, but also in terms of securing validation from the U.S. Food and Federal Drug Administration (FDA), and seeking approval by the National Medical Products Administration (NMPA), previously the China Food and Drug Administration (CFDA), which is the institution responsible for pharmaceuticals and medical device regulations in China," said Charles Martin, Chief Executive Officer of CBSC. "Beyond the obvious manufacturing and regulatory approval advantages gained through this valuable relationship, the cooperative alliance will also provide multiple gateways directly into existing distribution channels throughout the region once we commence full-rate production."As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.About CB Scientific, Inc.CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.Company Contact Information:Telephone: (888) 225-0870Email: General Inquiries: [email protected] Inquiries: Robert Hesse - [email protected] CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and NewsletterThis information dis...